Brief: 3Sbio Says Clinical Trial Application Approved By National Medical Products Administration
01/08/2019 15:59
Aug 1 (Reuters) - 3SBio Inc 1530.HK :
* CLINICAL TRIAL APPLICATION OF RECOMBINANT HUMANIZED
ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY INJECTION SOLUTION
APPROVED BY NMPA
* NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED GROUP'S
APPLICATION ON 31 JULY 2019
Source text for Eikon: ID:nHKS9cPsYH
Further company coverage: 1530.HK
((Reuters.Briefs@thomsonreuters.com;))